Hamid Riazi-Esfahani, Amin Ahmadi, Reza Sadeghi, Masoud Mirghorbani, Fariba Ghassemi, Mohammad Zarei, Hassan Khojasteh, Nikoo Bayan, Hooshang Faghihi, Elias Khalili Pour, Ahmad Mirshahi
{"title":"通过光学相干断层扫描血管造影术评估泛视网膜光凝与玻璃体内抗血管内皮生长因子注射后的眼窝血管。","authors":"Hamid Riazi-Esfahani, Amin Ahmadi, Reza Sadeghi, Masoud Mirghorbani, Fariba Ghassemi, Mohammad Zarei, Hassan Khojasteh, Nikoo Bayan, Hooshang Faghihi, Elias Khalili Pour, Ahmad Mirshahi","doi":"10.18502/jovr.v19i3.13622","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to compare macular vascular changes one and three months after treatment with either panretinal photocoagulation (PRP) or intravitreal bevacizumab (IVB).</p><p><strong>Methods: </strong>A total of 62 eyes with very severe non-proliferative diabetic retinopathy or early proliferative diabetic retinopathy without center-involved diabetic macular edema, were included in this retrospective study. Thirty-nine eyes were allocated to the PRP group, while 23 eyes were treated with IVB. Optical coherence tomography angiography (OCTA) was performed to measure foveal avascular zone (FAZ) characteristics as well as the densities of superficial and deep capillary plexuses (SCP and DCP).</p><p><strong>Results: </strong>In the IVB group, the FAZ area and perimeter expanded at month one but returned to baseline level after three months. In the PRP group, however, the FAZ area and perimeter were rather steady. Changes in the FAZ area were significantly different between the treatment groups at month one (<i>P</i> = 0.02), but not at month three (<i>P</i> = 0.31). There was no significant difference in the change in FAZ circularity index between the two groups at each time point (<i>P</i> = 0.55 and <i>P</i> = 0.31). Similarly, changes in SCP density were not statistically significant between the two groups at both time points (all <i>Ps</i> <math><mo>></mo></math> 0.05). A comparison of the two treatment arms based on the mean change in DCP density revealed a significant difference at month one, but not at month three (<i>P</i> = 0.01 and <i>P</i> = 0.49, respectively).</p><p><strong>Conclusion: </strong>Although bevacizumab and PRP have different short-term macular vascular responses, both therapies have the ability to normalize or stabilize vascular measures over time.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"313-323"},"PeriodicalIF":1.6000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443997/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of Foveal Vasculature by Optical Coherence Tomography Angiography after Pan-Retinal Photocoagulation versus Intravitreal Anti-VEGF Injections.\",\"authors\":\"Hamid Riazi-Esfahani, Amin Ahmadi, Reza Sadeghi, Masoud Mirghorbani, Fariba Ghassemi, Mohammad Zarei, Hassan Khojasteh, Nikoo Bayan, Hooshang Faghihi, Elias Khalili Pour, Ahmad Mirshahi\",\"doi\":\"10.18502/jovr.v19i3.13622\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to compare macular vascular changes one and three months after treatment with either panretinal photocoagulation (PRP) or intravitreal bevacizumab (IVB).</p><p><strong>Methods: </strong>A total of 62 eyes with very severe non-proliferative diabetic retinopathy or early proliferative diabetic retinopathy without center-involved diabetic macular edema, were included in this retrospective study. Thirty-nine eyes were allocated to the PRP group, while 23 eyes were treated with IVB. Optical coherence tomography angiography (OCTA) was performed to measure foveal avascular zone (FAZ) characteristics as well as the densities of superficial and deep capillary plexuses (SCP and DCP).</p><p><strong>Results: </strong>In the IVB group, the FAZ area and perimeter expanded at month one but returned to baseline level after three months. In the PRP group, however, the FAZ area and perimeter were rather steady. Changes in the FAZ area were significantly different between the treatment groups at month one (<i>P</i> = 0.02), but not at month three (<i>P</i> = 0.31). There was no significant difference in the change in FAZ circularity index between the two groups at each time point (<i>P</i> = 0.55 and <i>P</i> = 0.31). Similarly, changes in SCP density were not statistically significant between the two groups at both time points (all <i>Ps</i> <math><mo>></mo></math> 0.05). A comparison of the two treatment arms based on the mean change in DCP density revealed a significant difference at month one, but not at month three (<i>P</i> = 0.01 and <i>P</i> = 0.49, respectively).</p><p><strong>Conclusion: </strong>Although bevacizumab and PRP have different short-term macular vascular responses, both therapies have the ability to normalize or stabilize vascular measures over time.</p>\",\"PeriodicalId\":16586,\"journal\":{\"name\":\"Journal of Ophthalmic & Vision Research\",\"volume\":\"19 3\",\"pages\":\"313-323\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443997/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ophthalmic & Vision Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/jovr.v19i3.13622\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmic & Vision Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/jovr.v19i3.13622","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在比较使用全视网膜光凝(PRP)或玻璃体内贝伐单抗(IVB)治疗1个月和3个月后的黄斑血管变化:这项回顾性研究共纳入了62只患有非常严重的非增殖性糖尿病视网膜病变或早期增殖性糖尿病视网膜病变且无中心参与的糖尿病黄斑水肿的眼睛。39 只眼睛被分配到 PRP 组,23 只眼睛接受 IVB 治疗。研究人员进行了光学相干断层血管造影(OCTA),以测量眼窝血管缺损区(FAZ)的特征以及浅层和深层毛细血管丛(SCP和DCP)的密度:结果:在 IVB 组中,FAZ 的面积和周长在一个月时有所扩大,但在三个月后又恢复到基线水平。而在 PRP 组,FAZ 面积和周长相当稳定。治疗组之间的 FAZ 面积变化在第一个月有显著差异(P = 0.02),但在第三个月没有显著差异(P = 0.31)。两组在每个时间点的 FAZ 圆度指数变化没有明显差异(P = 0.55 和 P = 0.31)。同样,在两个时间点,SCP 密度的变化在两组之间也没有统计学意义(所有 Ps 均大于 0.05)。根据 DCP 密度的平均变化对两个治疗组进行比较后发现,在第一个月,两个治疗组之间存在显著差异,但在第三个月则不存在显著差异(分别为 P = 0.01 和 P = 0.49):结论:尽管贝伐单抗和PRP的短期黄斑血管反应不同,但这两种疗法都能使血管指标趋于正常或长期稳定。
Evaluation of Foveal Vasculature by Optical Coherence Tomography Angiography after Pan-Retinal Photocoagulation versus Intravitreal Anti-VEGF Injections.
Purpose: This study aimed to compare macular vascular changes one and three months after treatment with either panretinal photocoagulation (PRP) or intravitreal bevacizumab (IVB).
Methods: A total of 62 eyes with very severe non-proliferative diabetic retinopathy or early proliferative diabetic retinopathy without center-involved diabetic macular edema, were included in this retrospective study. Thirty-nine eyes were allocated to the PRP group, while 23 eyes were treated with IVB. Optical coherence tomography angiography (OCTA) was performed to measure foveal avascular zone (FAZ) characteristics as well as the densities of superficial and deep capillary plexuses (SCP and DCP).
Results: In the IVB group, the FAZ area and perimeter expanded at month one but returned to baseline level after three months. In the PRP group, however, the FAZ area and perimeter were rather steady. Changes in the FAZ area were significantly different between the treatment groups at month one (P = 0.02), but not at month three (P = 0.31). There was no significant difference in the change in FAZ circularity index between the two groups at each time point (P = 0.55 and P = 0.31). Similarly, changes in SCP density were not statistically significant between the two groups at both time points (all Ps 0.05). A comparison of the two treatment arms based on the mean change in DCP density revealed a significant difference at month one, but not at month three (P = 0.01 and P = 0.49, respectively).
Conclusion: Although bevacizumab and PRP have different short-term macular vascular responses, both therapies have the ability to normalize or stabilize vascular measures over time.